SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Cowen and Company 37th Annual Health Care Conference in Boston. Chief Executive Officer Mary Szela is scheduled to present on Wednesday, March 8, 2017 at 8:40 a.m. EST.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
